Market News & Trends
Verista Expands Automation & Validation Capabilities With Acquisition of Integral Solutions
Verista recently announced the acquisition of Integral Solutions. Based in Columbus, OH, Integral Solutions is a life sciences business and technology services firm that specializes in…
Sharp Sterile Manufacturing Increases Capacity With $28-Million Investment
Sharp Sterile Manufacturing recently announced a $28-million expansion of its site in Lee, MA. The enhanced state-of-the-art facility will strengthen opportunities for highly skilled engineering…
ProBioGen & Zag Bio Forge Strategic CMC Partnership to Advance Fc-Fusion Autoimmune Therapy
ProBioGen recently announced the signing of a Master Service Agreement (MSA) with Zag Bio, Inc., a biotechnology company developing thymus-targeted therapies to induce central immune…
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell Shuttle Platform
Autolus Therapeutics plc and Cellares Corp recently announced that Autolus will assess the feasibility of Cellares’ Cell Shuttle platform to complement its commercial manufacturing operations…
Nimbus Therapeutics Announces Research Collaboration & License Agreement With Lilly for Novel Oral Obesity Treatment
Nimbus Therapeutics, LLC recently announced it has entered into a multi-year research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company to develop…
FDA Approves New 2-Gram Presentation of Fibryga, Enhancing Convenience & Precision in Treating Acquired Fibrinogen Deficiency
Octapharma USA, Inc. recently announced the US FDA has approved a new 2-gram presentation of Fibryga, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for fibrinogen replacement…
Zenas BioPharma Announces Positive Results from Phase 3 Trial of Obexelimab in Immunoglobulin G4-Related Disease
Zenas BioPharma, Inc. recently announced positive results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD). Obexelimab met the primary endpoint,…
Protara Therapeutics Receives Both FDA Breakthrough Therapy & Fast Track Designations for TARA-002 in Pediatric Patients With Lymphatic Malformations
Protara Therapeutics, Inc. recently announced the US FDA has granted both Breakthrough Therapy and Fast Track designations for TARA-002, the Company’s investigational cell-based therapy, for…
FUJIFILM Irvine Scientific Now Officially FUJIFILM Biosciences
FUJIFILM Biosciences recently announced it has officially changed its legal name from FUJIFILM Irvine Scientific, Inc., to FUJIFILM Biosciences Inc., effective January 1, 2026. The…
Symbiosis Begins Commercial Manufacturing at New FDA-Inspected Facility
Symbiosis Pharmaceutical Services (Symbiosis) has recently manufactured its first 10,000 vial batch at the company’s new facility in Stirling, UK. The project, delivered for one of…
Medicus Pharma Announces Engagement With Reliant AI to Develop AI-Driven Clinical Data Analytics Platform
Medicus Pharma Ltd. recently announced it has entered into non-binding letter of intent (LOI) with Reliant AI Inc., a decision-intelligence company for the life sciences, specializing in…
Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of a Novel WRN Inhibitor for MSI-H Tumors
Nimbus Therapeutics, LLC recently announced the completion of dose escalation (Part A) in its Phase 1/2 clinical trial of NDI-219216, the company’s investigational non-covalent Werner…
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 in the Prevention of Chemotherapy-Induced Peripheral Neuropathy
MediciNova, Inc. recently announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in…
Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients
Brainomix recently announced results from its partnership with Argenica Therapeutics for imaging and clinical data analysis of the Phase II trial evaluating ARG-007, a neuroprotective…
PADCEV Plus Keytruda Significantly Improves Survival for Patients With Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Astellas Pharma Inc. and Pfizer Inc. recently announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial (also known as…
BaseLaunch Announces the Addition of Takeda as New Pharmaceutical Partner to its Biotech Venture Incubator
BaseLaunch, a platform to launch, fund, and build early biotech ventures developing cutting-edge therapeutics, announced today Takeda has joined the Basel-based incubator, bringing the total…
Affibody Accelerates Phase 1 Study with ABY-271 Following Initial Patient Data
Affibody AB recently announced the Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand Therapy (RLT) candidate ABY-271…
Lindus Health & Quotient Sciences Partner to Accelerate Drug Development From First-in-Human to Pivotal Trials
Lindus Health and Quotient Sciences have announced a strategic partnership to enable innovative biotech and pharma sponsors with enhanced patient recruitment for Phase I-IIa clinical studies and…
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline
Bicycle Therapeutics plc (NASDAQ: BCYC) recently announced it has entered into a 15-year contract including an option to renew with the UK Nuclear Decommissioning Authority (NDA)…
Peapod Bio & Enamine Announce Strategic Collaboration
Peapod Bio Inc. recently announced a strategic collaboration with Enamine, enabling Peapod Bio to offer its clients fully integrated screening campaigns with access to Enamine’s…
